Novel approaches to treatingClostridium difficile-associated colitis
- 7 December 2015
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Gastroenterology & Hepatology
- Vol. 10 (2) , 193-204
Abstract
Clostridium difficile is being recognized as a growing threat to many health-care systems. Epidemiology data shows that infection rates are soaring and the disease burden is increasing. Despite the efficacy of standard treatments, it is becoming evident that novel therapeutics will be required to tackle this disease. These new treatments aim to enhance the intestinal microbial barrier, activate the immune system and neutralize the toxins that mediate this disease. Many of these therapies are still in the beginning stages of investigation, however, in the next few years, more clinical data will become available to help implement many of these exciting new therapeutic approaches.Keywords
This publication has 97 references indexed in Scilit:
- Evaluation of an Oral Suspension of VP20621, Spores of Nontoxigenic Clostridium difficile Strain M3, in Healthy SubjectsAntimicrobial Agents and Chemotherapy, 2012
- In Vitro and In Vivo Characterization of CB-183,315, a Novel Lipopeptide Antibiotic for Treatment of Clostridium difficileAntimicrobial Agents and Chemotherapy, 2012
- Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disordersTherapeutic Advances in Gastroenterology, 2011
- Clostridial Binary Toxins: Iota and C2 Family PortraitsFrontiers in Cellular and Infection Microbiology, 2011
- Clostridium difficile Toxin CDT Induces Formation of Microtubule-Based Protrusions and Increases Adherence of BacteriaPLOS Pathogens, 2009
- Review article: anti‐inflammatory mechanisms of action of Saccharomyces boulardiiAlimentary Pharmacology & Therapeutics, 2009
- Increase in Adult Clostridium difficile –related Hospitalizations and Case-Fatality Rate, United States, 2000–2005Emerging Infectious Diseases, 2008
- Comparative Efficacies of Rifaximin and Vancomycin for Treatment of Clostridium difficile -Associated Diarrhea and Prevention of Disease Recurrence in HamstersAntimicrobial Agents and Chemotherapy, 2008
- Increase in Clostridium difficile –related Mortality Rates, United States, 1999 – 2004Emerging Infectious Diseases, 2007
- In Vitro Activities of 15 Antimicrobial Agents against 110 Toxigenic Clostridium difficile Clinical Isolates Collected from 1983 to 2004Antimicrobial Agents and Chemotherapy, 2007